How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

References

• Drummond M, Sculpher MJ, Claxton K, et al. Methods for the economics evaluation of health care programmes. 4th ed. Oxford University Press, Oxford, MS,USA; 2015.
   Google Scholar
• Neumann P, Sanders G, Russel L, et al. Cost-effectiveness in health and medicine. 2nd ed. Oxford University Press, Oxford, MS,USA; 2017.
   Google Scholar
• Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics. 2014;32(4):319–15.
   Web of Science ®Google Scholar
• Bonanni P, Picazo JJ, Remy V. The intangible benefits of vaccination - what is the true economic value of vaccination? J Mark Access Health Policy. 2015;3: 26964
   PubMedGoogle Scholar
• Szucs T, Quilici S, Panfilo M. From population to public institutions: what needs to be changed to benefit from the full value of vaccination. J Mark Access Health Policy. 2015;3: 26965
   PubMedGoogle Scholar
• Standaert B, Rappuoli R. 3. How comprehensive can we be in the economic assessment of vaccines? J Mark Access Health Policy. 2017;5(1):1336044.
   PubMedGoogle Scholar
• Gessner BD, Kaslow D, Louis J, et al. Estimating the full public health value of vaccination. Vaccine. 2017;35(46):6255–6263.
   Web of Science ®Google Scholar
• Lam E, Schluter WW, Masresha BG, et al. Development of a district-level programmatic assessment tool for risk of measles virus transmission. Risk Anal. 2017;37(6):1052–1062.
   Web of Science ®Google Scholar
• Standaert B, Rappuoli R. Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination. J Mark Access Health Policy. 2017;5(1):1335162.
   PubMedGoogle Scholar
• Bruijning-Verhagen P, van Dongen JAP, Verberk JDM, et al. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting. BMC Med. 2018;16(1):168.
   PubMedGoogle Scholar
• Cutting WA. Cost-benefit evaluations of vaccination programmes. Lancet. 1980;2(8195 pt 1):634–635.
   Web of Science ®Google Scholar
• Mauskopf J, Standaert B, Connolly MP, et al. Economic analysis of vaccination programs. Value Health. 2018;21(10):1133–1149.
   PubMed Web of Science ®Google Scholar
• Standaert B. Are changes occurring in the perceived value of vaccines? Belg Paeds. 2016;18:321–323.
   Google Scholar
• Bloom DE, Canning D, Jamison DT. Health, wealth, and welfare. Finance Dev. 2004;41:10–15.
   Google Scholar
• Jit M, Hutubessy R, Png ME, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209.
   PubMed Web of Science ®Google Scholar
• van der Putten IM, Evers SM, Deogaonkar R, et al. Stakeholders’ perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. BMC Public Health. 2015;15:356.
   Web of Science ®Google Scholar
• Saadatian-Elahi M, Horstick O, Breiman RF, et al. Beyond efficacy: the full public health impact of vaccines. Vaccine. 2016;34(9):1139–1147.
   Web of Science ®Google Scholar
• Standaert B, Rappuoli R. 2. How is the economic assessment of vaccines performed today? J Mark Access Health Policy. 2017;5(1):1335163.
   PubMedGoogle Scholar
• Sanders JL. Quantitative guidelines for communicable disease control programs. Biometrics. 1971;27(4):883–893.
   Web of Science ®Google Scholar
• Sethi SP. Quantitative guidelines for communicable disease control program: a complete synthesis. Biometrics. 1974;30(4):681–691.
   Web of Science ®Google Scholar
• Grab B, Cvjetanovic B. Simple method for rough determination of the cost-benefit balance point of immunization programmes. Bull World Health Organ. 1971;45(4):536–541.
   Web of Science ®Google Scholar
• Zerbe RD. Benefit-cost analysis. New York, NY: HarperCollins College Publishers; 1994. p. 551.
   Google Scholar
• Blume S. The erosion of public sector vaccine production: the case of the Netherlands. In: Holmberg C, Blume S, Greenough P, editors. The politics of vaccination. Manchester University Press, Manchester, UK; 2017. p. 148–173.
   Google Scholar
• Barnum HN, Tarantola D, Setiady IF. Cost-effectiveness of an immunization programme in Indonisia. Bull World Health Organ. 1980;58(3):499–503.
   Web of Science ®Google Scholar
• Willems JS, Sanders CR, Riddiough MA, et al. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med. 1980;303(10):553–559.
   PubMed Web of Science ®Google Scholar
• Jonsson B, Horisberger B, Bruguera M, et al. Cost-benefit analysis of hepatitis-B vaccination: A computerized decision model for Spain. Int J Technol Assess Health Care. 1991;7(3):379–402.
   Google Scholar
• Dienstag JL, Silverstein MD, Mulley AG. The cost-effectiveness of hepatitis B vaccine. J Infect. 1983;7(Suppl 1):81–84.
   Google Scholar
• Vanderslott S, Dadonaite B, Roser M. Vaccination; 2018. Available from: https://ourworldindata.org/vaccination
   Google Scholar
• Anderson RM, May R. Infectious diseases of humans. Oxford: Oxford University Press; 1991.
   Google Scholar
• Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460–1468.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–4214.
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20(7–8):1113–1125.
   Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.
   PubMed Web of Science ®Google Scholar
• Brisson M, Melkonyan G, Drolet M, et al. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine. 2010;28(19):3385–3397.
   Web of Science ®Google Scholar
• Atkins KE, Shim E, Pitzer VE, et al. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine. 2012;30(3):552–564.
   Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Melegaro A, et al. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine. 2002;20(9–10):1316–1330.
   PubMed Web of Science ®Google Scholar
• Barnighausen T, Berkley S, Bhutta ZA, et al. Reassessing the value of vaccines. Lancet Glob Health. 2014;2(5):e251–2.
   Web of Science ®Google Scholar
• Deogaonkar R, Hutubessy R, van der Putten I, et al. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012;12:878.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy. 2016;14(3):245–252.
   PubMed Web of Science ®Google Scholar
• Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30(4):337–353.
   Web of Science ®Google Scholar
• Standaert BA, Curran D, Postma MJ. Budget constraint and vaccine dosing: a mathematical modelling exercise. Cost Eff Resour Alloc. 2014;12(1):3.
   Web of Science ®Google Scholar
• Sauboin C, Van Vlaenderen I, Van Bellinghen LA, et al. Reducing malaria mortality at the lowest budget: an optimization tool for selecting malaria preventative interventions applied to Ghana. MDM Policy Pract. 2019;4(2):2381468319861346.
   Google Scholar
• Standaert B, Van Vlaenderen I, Van Bellinghen L-A, et al. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019. doi:10.1007/s40258-019-00534-y. [Epub ahead of print]
   Web of Science ®Google Scholar
• Standaert B, Schecroun N, Ethgen O, et al. Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains. Health Policy. 2017;121(12):1303–1312.
   Web of Science ®Google Scholar
• Connolly MP, Topachevskyi O, Standaert B, et al. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics. 2012;30(8):681–695.
   Web of Science ®Google Scholar
• Kotsopoulos N, Haitsma G, Connolly MP, et al. Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework. Expert Rev Pharmacoecon Outcomes Res. 2019. doi: 10.1080/14737167.2020.1693269. [Epub ahead of print]
   Web of Science ®Google Scholar
• Passarella R. Handbook on social accounting matrices and labour accounts. 2003; Available from: http://forum.europa.eu.int/Members/inc/dsis/employ/home
   Google Scholar
• Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1–31.
   PubMed Web of Science ®Google Scholar
• Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis. 2008;8(11):727–733.
   Web of Science ®Google Scholar
• Standaert B, Alwan A, Strens D, et al. Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: an evaluation study in Belgium. Hum Vaccin Immunother. 2015;11(9):2266–2273.
   PubMed Web of Science ®Google Scholar
• Ganiats TG. Prevention, policy, and paradox: what is the value of future health? Am J Prev Med. 1997;13(1):12–17.
   Web of Science ®Google Scholar
• Brouwer WB, Niessen LW, Postma MJ, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446–448.
   PubMedGoogle Scholar
• Standaert B, Ethgen O, Emerson R, et al. Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn? Adv Ther. 2014;31(10):1095–1108.
   Web of Science ®Google Scholar
• Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32(6):525–531.
   PubMed Web of Science ®Google Scholar
• Robinson LA, Hammitt JK, Chang AY, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–145.
   PubMed Web of Science ®Google Scholar
• Ferko N, Postma M, Gallivan S, et al. Evolution of the health economics of cervical cancer vaccination. Vaccine. 2008;26(Suppl 5):F3–15.
   Google Scholar
• Hanquet G, Valenciano M, Simondon F, et al. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31(48):5634–5642.
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health. 2016;19(5):558–566.
   PubMed Web of Science ®Google Scholar
• Berkley S. Improving access to vaccines through tiered pricing. Lancet. 2014;383(9936):2265–2267.
   Web of Science ®Google Scholar
• Dort T, Schecroun N, Standaert B. Improving the hospital quality of care during winter periods by optimizing budget allocation between rotavirus vaccination and bed expansion. Appl Health Econ Health Policy. 2018;16(1):123–132.
   PubMed Web of Science ®Google Scholar
• Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146(10):789–803.
   PubMed Web of Science ®Google Scholar
• Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine. 2014;32(26):3133–3138.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Longini I, Zuber PL, et al. The public health value of vaccines beyond efficacy: methods, measures and outcomes. BMC Med. 2017;15(1):138.
   Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in health care decisions. Int J Technol Assess Health Care. 2011;27(1):5.
   Web of Science ®Google Scholar
• Garrison LP Jr., Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health. 2017;20(2):213–216.
   PubMed Web of Science ®Google Scholar
• Marchionatti RMF. Considerations on the fundamental principles of pure political economy. New York, NY: Rotledge; 2007.
   Google Scholar
• Largeron N, Lévy P, Wasem J, et al. Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy. 2015;3:27043.
   PubMedGoogle Scholar
• Nelson AL, Cohen JT, Greenberg D, et al. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med. 2009;151(9):662–667.
   PubMed Web of Science ®Google Scholar
• Verguet S, Kim JJ, Jamison DT. Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics. 2016;34(9):913–923.
   PubMed Web of Science ®Google Scholar
• Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Med Decis Making. 2016;36(1):8–19.
   PubMed Web of Science ®Google Scholar
• Marsh K, IJzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making–emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(2):125–137.
   PubMed Web of Science ®Google Scholar
• Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making–an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13.
   PubMed Web of Science ®Google Scholar
• Lahdelma R, Salminen P. Stochastic Multicriteria Acceptability Analysis (SMAA). In: Ehrgott M, Figueira JR, Greco S, editors. Trends in multiple criteria decision analysis. Boston, MA: Springer US; 2010. p. 285–315.
   Google Scholar
• Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13(3):277–288.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Earnshaw S. Budget-impact analysis of health care interventions, a practical guide. Adis, Cham, Switzerland; 2017.
   Google Scholar
• Prue G, Baker P, Graham D, et al. It is time for universal HPV vaccination. Lancet. 2018;392(10151):913–914.
   Web of Science ®Google Scholar
• Crown W, Buyukkaramikli N, Thokala P, et al. Constrained optimization methods in health services research-an introduction: report 1 of the ISPOR optimization methods emerging good practices task force. Value Health. 2017;20(3):310–319.
   PubMed Web of Science ®Google Scholar
• Crown W, Buyukkaramikli N, Sir MY, et al. Application of constrained optimization methods in health services research: report 2 of the ISPOR optimization methods emerging good practices task force. Value Health. 2018;21(9):1019–1028.
   PubMed Web of Science ®Google Scholar
• Sarker R, Newton C. Optimization Modelling, a practical approach. CRC Press, Taylor & Francis Group, Boca Raton, FL, USA; 2008.
   Google Scholar
• Connolly MP, Kotsopoulos N, Postma MJ, et al. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health. 2017;20(2):273–277.
   PubMed Web of Science ®Google Scholar
• Rodriguez GN. Social accounting matrix and analysis of productive sectors in Mexico. Contaduria y Administracion. 2018;63(1):1–28.
   Google Scholar
• Kotsopoulos N, Connolly MP, Postma MJ, et al. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine. 2013;31(46):5430–5434.
   PubMed Web of Science ®Google Scholar
• Masters R, Anwar E, Collins B, et al. Return on investment of public health interventions: a systematic review. J Epidemiol Community Health. 2017;71(8):827–834.
   PubMed Web of Science ®Google Scholar
• Adler MD, Fleurbaey M. The Oxford Handbook of well-being and public policy. 1st ed. Oxford University Press, Oxford, MS, USA; 2016.
   Google Scholar
• Attema AE. Incorporating sign-dependence in health-related social welfare functions. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):223–228.
   PubMed Web of Science ®Google Scholar
• Doherty M, Buchy P, Standaert B, et al. Vaccine impact: benefits for human health. Vaccine. 2016;34(52):6707–6714.
   PubMed Web of Science ®Google Scholar
• Poulos C, Standaert B, Sloesen B, et al. Preferences for vaccines against children’s diarrheal illness among mothers in Poland and Hungary. Vaccine. 2018;36(40):6022–6029.
   PubMed Web of Science ®Google Scholar
• Yerushalmi E, Hunt P, Hoorens S, et al. Exploring the use of a general equilibrium method to assess the value of a malaria vaccine: an application to Ghana. Med Decis Making Policy Pract. 2019;4(2):2381468319894345.
   Google Scholar
• Standaert B, Strens D, Alwan A, et al. Medium- to long-term impact of rotavirus vaccination on hospital care in Belgium: A 7-year follow-up of the Rotavirus Belgium Impact Study (RotaBIS). Infect Dis Ther. 2016;5(1):31–44.
   PubMed Web of Science ®Google Scholar
• Sauboin C, Mihajlović J, Geets R, et al. A new way to inform decision-maker and enhance vaccination programs in countries with limited budgets - the case of Serbia. Presented at ISPOR Europe; 2019 November; Copenhagen, Denmark.
   Google Scholar
• World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes; 2019 [ 2019 Oct 1 2019 Dec 9]. Available from: https://www.who.int/immunization/newsroom/news_guidance_stadard_economic_eval_imm_programmes/en/
   Google Scholar